FARON.HE Faron Pharmaceuticals Oy

Healthcare Biotechnology Helsinki Exchange
0.3830 EUR
Close of Oct 29, 2026
0.3750 2.41
Market cap
EUR 77.7M
P/E
-
P/B
6.60x
ROE
-
Dividend yield
-
Fundamental score
0.9/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is FARON.HE undervalued?

Graham number

The Graham number of Faron Pharmaceuticals Oy cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Faron Pharmaceuticals Oy fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-235.8%), below 10%.

ROA 0/1

Return on assets (-76.1%) is below the industry median (-19.8%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (3.8%) is below the industry median (3.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (79.8%), up to 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 1/2

Cash covers 1.8 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (6.6x) is above the industry median (3.1x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Faron Pharmaceuticals Oy stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combina…

Full company profile